Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may lead to severe disease in some
cases, leading to acute respiratory distress syndrome, multi-organ failure, and death. This severe phenotype
seems to be associated with a cytokine storm and immune dysregulation. Increased pro-inflammatory cytokines
and CD14+CD16+ inflammatory monocytes, lymphopenia, and decreased levels of regulatory T cells are some
of the immunological features that are seen in patients with SARS-CoV-2. As the outcome of SARS-CoV-2 is
influenced by both viral virulence and dysregulated inflammatory response, a combination therapy approach
using antiviral drugs plus anti-inflammatory treatments, such as corticosteroids, monoclonal antibodies against
the IL-6 and IL-1β pathways, and JAK inhibitors are under clinical trials.